Clinical observation on treatment of hypertension (yin-deficiency with sthenic-yang syndrome type) with Zhongfu Hypotension Capsule.
- Author:
Qiu-ai KOU
1
;
Hua-ping YU
;
Guo-dong ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; therapeutic use; Benzazepines; therapeutic use; Blood Pressure; drug effects; Double-Blind Method; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Hypertension; drug therapy; physiopathology; Male; Middle Aged; Phytotherapy; Syndrome; Tablets; Yin Deficiency; drug therapy; pathology
- From: Chinese Journal of Integrated Traditional and Western Medicine 2007;27(8):745-748
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and safety of zhongfu hypotension capsule (ZHC) in treating hypertension of yin-deficiency with sthenic-yang syndrome type.
METHODSAdopting the stratified, block randomized, double-blinded, double-dummy, positive parallel controlled, multi-centered clinical trial method, the tested group was treated by orally taken 3 capsules of ZHC (0.5 g/capsule) twice a day, and the control group was treated by orally taken Lotensin Tablet 1 tablet (10 mg/tab.) once a day. And all received the adiaphorous drug with the dosage-form mimic to that used in the tested group. The therapeutic course was 4 weeks for both groups.
RESULTSThe markedly effective rate and the total effective rate in reducing blood pressure was 58.65% and 79.81% respectively in the tested group, and 60.51% and 78.34% respectively in the control group; while the markedly effective rate and the total effective rate for alleviating TCM syndrome was 21.15% and 78.85% in the tested group, and 25.48% and 86.62% in the control group respectively. Comparisons between the two groups showed insignificant difference (P > 0.05).
CONCLUSIONZHC has good efficacy and is safety in treating hypertension.
